DEGARELIX for Neoplasm malignant: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 19 adverse event reports in the FDA FAERS database where DEGARELIX was used for Neoplasm malignant.
Most Reported Side Effects for DEGARELIX
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Injection site pain | 296 | 7.8% | 13 | 52 |
| Injection site erythema | 246 | 6.5% | 6 | 46 |
| Hot flush | 199 | 5.3% | 2 | 28 |
| Fatigue | 195 | 5.2% | 6 | 61 |
| Injection site swelling | 183 | 4.8% | 3 | 25 |
| Product storage error | 177 | 4.7% | 0 | 0 |
| Pyrexia | 170 | 4.5% | 8 | 96 |
| Off label use | 128 | 3.4% | 16 | 35 |
| Asthenia | 123 | 3.3% | 11 | 47 |
| Death | 120 | 3.2% | 116 | 33 |
| Injection site mass | 118 | 3.1% | 2 | 11 |
| Malaise | 117 | 3.1% | 9 | 65 |
| Fall | 113 | 3.0% | 9 | 80 |
| Prostatic specific antigen increased | 111 | 2.9% | 9 | 26 |
| Interstitial lung disease | 109 | 2.9% | 16 | 72 |
Other Indications for DEGARELIX
Prostate cancer (2,035)
Product used for unknown indication (1,046)
Prostate cancer metastatic (237)
Hormone-dependent prostate cancer (187)
Hormone-refractory prostate cancer (102)
Prostatic specific antigen increased (13)
Bone cancer (11)
Metastases to bone (11)
Prostate cancer stage iv (8)
Hormone therapy (7)
Other Drugs Used for Neoplasm malignant
PALBOCICLIB (1,996)
CAPECITABINE (1,493)
PEMBROLIZUMAB (1,135)
PACLITAXEL (984)
CARBOPLATIN (977)
NIVOLUMAB (947)
OXALIPLATIN (823)
PAZOPANIB (716)
CYCLOPHOSPHAMIDE (685)
FLUOROURACIL (676)